MCK241115P645000
- 0.00
- 0.000.00%
McKesson Newsroom
Weekly Buzz: Not All Parties Last Forever
Market Falls to End All-Time High Week | Wall Street Today
Market Falls Friday After Light Earnings and 13F's | Live Stock
Market Falls Thursday, Powell Said Fed Will Take Things Slow | Wall Street Today
AZURITY PHARMACEUTICALS, INC ANNOUNCES FDA APPROVAL OF DANZITEN (Nilotinib) Tablets, THE FIRST AND ONLY NILOTINIB WITH NO MEALTIME RESTRICTIONS
McKesson's (NYSE:MCK) Conservative Accounting Might Explain Soft Earnings
Thursday Market Chills From Election Celebration | Live Stock
Express News | InspiroGene by McKesson Partners With Vertex To Expand Distribution Of CASGEVY, The First FDA-Approved CRISPR Gene-Editing Therapy For Sickle Cell Disease And Β-Thalassemia
Investors Can Find Comfort In McKesson's (NYSE:MCK) Earnings Quality
Bitcoin Gets Closer to $100k Than Ever | Wall Street Today
McKesson Analyst Ratings
All You Need to Know About McKesson (MCK) Rating Upgrade to Buy
Bitcoin Breaks Above $90k, Market Flat Wednesday | Live Stock
McKesson (MCK) Is Considered a Good Investment by Brokers: Is That True?
Investors Heavily Search McKesson Corporation (MCK): Here Is What You Need to Know
Citi Maintains McKesson(MCK.US) With Buy Rating, Raises Target Price to $713
Express News | Mckesson Corp : Citigroup Raises Target Price to $713 From $630
Analysts Conflicted on These Healthcare Names: McKesson (MCK), Fate Therapeutics (FATE) and Voyager Therapeutics (VYGR)
Argus Adjusts Price Target on McKesson to $660 From $570
Tuesday Market Finally Slows Down, Takes a Post Veterans Day Breather | Live Stock